40,000+ diagnosed patients · 30+ indications · 14 markets · used by 6 of the top 20 global life science companies
Pharma commercial teams are rebuilding the patient journey around AI-powered patient interviews at scale. Across our engagements, the methodology already runs underneath launch planning, brand strategy, and payer dossiers at top-twenty pharma. The companies still working from the older approach are competing against it.
Industry analyses from McKinsey, Deloitte, EvaluatePharma, and IQVIA consistently put the drug launch failure rate at around 60%. Only 25% meet forecast. Just 15% exceed it.
Pharmaceutical companies spend between $475 and $830 million per launch on commercial activities. Market access planning, field force training, medical education, patient support, and omnichannel engagement. With that level of capital deployed before any revenue is realized, an underperforming launch puts hundreds of millions at risk.
Clinical success does not guarantee commercial success. The question every launch leader is asking: what does the 40% that beats forecast do differently?
Only 15% of launches exceed forecast. Clinical data alone does not predict that outcome.
Across our engagements, AI-powered patient interviews at scale now run underneath commercial decision-making at top-twenty pharma teams.
Across recent commercial launches, five drivers emerged consistently. Only one of them has anything to do with the drug itself.
Patient insight gaps account for 27% of launch failures. Second only to market access.
Launch teams that miss forecast almost always describe the same problem in hindsight: the patient they planned for wasn't the patient who showed up. Diagnosis was harder than expected. Side effects were worse. Adherence was lower. The patient journey map informing the launch reflected a reality that had already moved on.
Launches that exceed forecast share a different pattern. Their commercial teams worked from a continuously updated view of the patient journey, built from real patient data rather than periodic research, and they planned against the patient reality that actually existed at launch.
The methodology shift sounds incremental. The operational shift across commercial, medical, and access functions is not.
The friction between functions closes when the journey stops being a deliverable owned by one team and becomes the shared input every team plans against.
Three of the most-studied launch failures of the past decade. In every case, the clinical data was strong. The patient understanding wasn't.
Medicare restricted coverage. Doctors were unconvinced by mixed clinical data. High out-of-pocket costs and burdensome monitoring meant few patients could start therapy. Every root cause hit at once.
Severe diarrhea drove high discontinuation rates. Oncologists were unprepared to manage the side effect. The post-prescription journey was never mapped, and patients hit an adherence barrier the launch plan didn't address.
$14,000 annual price tag prompted strict prior authorization. Over 30% of patients prescribed discontinued therapy due to payer refusals. Access barriers killed uptake before patient experience could catch up.
Two real engagements with global pharma partners. Both started as a single-market pilot. Both scaled to a unified patient journey across multiple countries, built on real patient evidence, not internal assumption.
A top-10 global pharma pressure-tested their patient journey against quantitative patient data, rewrote where evidence diverged from assumption, and built a digital companion programme the field can actually plan against.
A top-20 biopharma entered a rare neurology indication with no prior commercial playbook. One pilot became the foundation for a pan-European patient intelligence contract that is now how leadership decides where to act.
Across the launches that meet or exceed forecast, three operational practices show up consistently. None require a different drug. All require a different relationship with patient evidence.
Don't wait until approval to address payer concerns. Engage payers in parallel with clinical development. Ground value narratives in patient-reported outcomes. Limited access drives 30% of failures. Excelling here is the single largest performance lever.
Commercial, medical, access, and HEOR teams build strategy from the same continuously updated view of the patient. Conflicting narratives close. Trade-offs get easier. The patient journey becomes shared ground truth, not a deliverable owned by one team.
Map the patient journey continuously. Symptom onset, diagnosis, access barriers, treatment initiation, side effects, adherence, switching. Lack of patient insight drives 27% of failures. The launches that win operate on what patients are actually experiencing, refreshed in near real time.
The launches beating forecast are already operating on it. The companies still working from the older methodology are competing against them. Same therapeutic areas. Same launch windows. Different input layer underneath the strategy.
All statistics on this page are drawn from mama health's 2026 analysis, Commercial Drug Launches: Why 60% Fail. External research is sourced to McKinsey & Company, Deloitte, IQVIA, EvaluatePharma, Health Advances, Indegene, and case-specific industry reporting.